ALNY - ALNYLAM PHARMACEUTICALS, INC.
IEX Last Trade
243.445
-29.635 -12.173%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:01:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$273.08
-29.64
-10.85%
Fundamental analysis
40%
Profitability
43%
Dept financing
26%
Liquidity
58%
Performance
36%
Performance
5 Days
-0.89%
1 Month
-3.08%
3 Months
-10.81%
6 Months
1.29%
1 Year
27.34%
2 Year
2.25%
Key data
Stock price
$243.44
DAY RANGE
$241.46 - $273.08
52 WEEK RANGE
$145.79 - $304.39
52 WEEK CHANGE
$23.75
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Yvonne L. Greenstreet
Region: US
Website: alnylam.com
Employees: 2,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: alnylam.com
Employees: 2,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Recent news